ARCT (Arcturus Therapeutics Holdings) EPS (Basic): $-2.81 (TTM As of Mar. 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
54 GF Score
Price $6.82
GF Value $4.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings EPS (Basic)?

Arcturus Therapeutics Holdings ARCT -2.71% 54 EPS (Basic) is $-2.81 as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Arcturus Therapeutics Holdings's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.95. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.81.

Arcturus Therapeutics Holdings's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.95. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.81.

Arcturus Therapeutics Holdings's EPS without NRI for the three months ended in Mar. 2026 was $-0.95. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -2.83.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Arcturus Therapeutics Holdings's highest 3-Year average EPS without NRI Growth Rate was 52.70% per year. The lowest was -89.40% per year. And the median was 0.80% per year.

Arcturus Therapeutics Holdings  (NAS:ARCT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Arcturus Therapeutics Holdings EPS (Basic) Related Terms

Arcturus Therapeutics Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings EPS (Basic) Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.74 0.35 -1.12 -3.00 -2.40

Arcturus Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.34 -0.49 -1.03 -0.95
ARCT
54GF Score
Arcturus Therapeutics Holdings Inc ARCT
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Arcturus Therapeutics Holdings's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-65.783-0)/27.386
=-2.40

Arcturus Therapeutics Holdings's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-26.964-0)/28.421
=-0.95

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-2.81 mean?
Arcturus Therapeutics Holdings (ARCT) has a EPS (Basic) of $-2.81 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arcturus Therapeutics Holdings and its competitors.
Is Arcturus Therapeutics Holdings' EPS (Basic) too high?
Arcturus Therapeutics Holdings' current EPS (Basic) is $-2.81. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' EPS (Basic) compare to YDES and RNAC?
Arcturus Therapeutics Holdings' EPS (Basic) of $-2.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current EPS (Basic) is $-2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.82 — trading 54.5% above its estimated fair value. The current EPS (Basic) is $-2.81. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current EPS (Basic) is $-2.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.82 is trading 54.5% above its estimated GF Value™ of $4.41. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • EPS (Basic): $-2.81
  • GF Value™: $4.41 vs. price of $6.82 (54.5% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score

Get the complete analysis for ARCT

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.82
Price
$4.41
GF Value